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The hexosamine biosynthetic pathway (HBP) gen-
erates uridine diphosphate N-acetylglucosamine
(UDP-GlcNAc) for glycan synthesis and O-linked
GlcNAc (O-GlcNAc) protein modifications. Despite
the established role of the HBP in metabolism and
multiple diseases, regulation of the HBP remains
largely undefined. Here, we show that spliced X-box
binding protein 1 (Xbp1s), the most conserved signal
transducer of the unfolded protein response (UPR),
is a direct transcriptional activator of the HBP. We
demonstrate that the UPR triggers HBP activation
via Xbp1s-dependent transcription of genes coding
for key, rate-limiting enzymes. We further establish
that this previously unrecognized UPR-HBP axis
is triggered in a variety of stress conditions. Finally,
we demonstrate a physiologic role for the UPR-HBP
axis by showing that acute stimulation of Xbp1s in
heart by ischemia/reperfusion confers robust car-
dioprotection in part through induction of the HBP.
Collectively, these studies reveal that Xbp1s couples
the UPR to the HBP to protect cells under stress.
INTRODUCTION
Posttranslational modification of proteins by O-linked coupling
of N-acetylglucosamine (GlcNAc) is a dynamic process that
governs the function of numerous proteins, both cytosolic and
nuclear. O-GlcNAc modifications have been implicated in phys-
iological and pathological responses to nutrient availability andcellular stress (Hanover et al., 2010; Zachara, 2012). Sustained
increases in O-GlcNAc protein modification have been sug-
gested to contribute to the pathogenesis of cancer, diabetes,
and neurodegenerative diseases (Lazarus et al., 2009; Slawson
and Hart, 2011). That said, acute upregulation of O-GlcNAc
modification promotes cell survival in the setting of various
stresses (Darley-Usmar et al., 2012; Zachara, 2012).
O-GlcNAcmodificationsaremediatedbyO-GlcNActransferase
(OGT), the sole and highly conserved enzyme that conjugates
O-GlcNAc groups to appropriate targets; its actions are dynami-
cally counteracted by O-GlcNAcase (Hart et al., 2011; Slawson
and Hart, 2011). The substrate of OGT is uridine diphosphate
N-acetylglucosamine (UDP-GlcNAc), a nucleotide sugar that is
the final product of the hexosamine biosynthetic pathway (HBP).
Generation of UDP-GlcNAc by the HBP provides a substrate
critical tomultiplebiological processes, includingO-GlcNAcmodi-
fication, N-glycan synthesis, and proteoglycan production. How-
ever, mechanisms governing activation of the HBP are unclear.
The unfolded protein response (UPR) is an evolutionarily
conserved cellular process to cope with protein folding stress
(Schro¨der and Kaufman, 2005; Walter and Ron, 2011). Accu-
mulation of misfolded proteins in the endoplasmic reticulum
(ER) lumen activates three major signal transducers, viz.
PERK, ATF6, and IRE1. The resulting ER stress response
retards protein translation, increases ER chaperone produc-
tion, and enhances ER-associated protein degradation
(ERAD), which together serve to restore cellular homeostasis.
The IRE1 pathway is the most ancient branch of the UPR, being
conserved from yeast to mammals (Hetz et al., 2011). IRE1,
when activated by phosphorylation, manifests endoribonu-
clease activity, which cleaves a cryptic exon of 26 bp from the
downstream target gene X-box binding protein 1 (Xbp1). The
resulting spliced Xbp1 (Xbp1s) is a highly active transcriptionCell 156, 1179–1192, March 13, 2014 ª2014 Elsevier Inc. 1179
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factor, which promotes gene expression of ER chaperones and
molecules involved in ERAD. Accumulating evidence suggests
that Xbp1s exerts strong prosurvival effects under various con-
ditions, including cancer cell proliferation (Romero-Ramirez
et al., 2004), plasma cell differentiation (Iwakoshi et al., 2003),
inflammatory bowel disease (Kaser et al., 2008), Alzheimer’s
disease (Casas-Tinto et al., 2011), and pancreatic acinar cell
differentiation (Hess et al., 2011).
Myocardial infarction is a leading cause of mortality worldwide
(Go et al., 2013). Restoration of blood flow to the infarct-related
artery provokes a second wave of cell death, as the cardiomyo-
cyte shifts to an oxygen-rich environment. Recent reports
show that ischemia/reperfusion (I/R) is associated with potent
increases in O-GlcNAc modification (Ngoh et al., 2011). We
therefore set out to investigate the regulation of the HBP and
O-GlcNAc modification under these conditions. Pathological
events occurring with I/R, including Ca2+ mishandling and reac-
tive oxygen species (ROS) accumulation, are potent inducers of
the UPR (Murphy and Steenbergen, 2008; Turer and Hill, 2010).
Here, we report that the HBP, O-GlcNAc protein modification,
and the UPR are each robustly activated in heart by I/R. We
demonstrate that the rate-limiting enzyme of the HBP, glutamine
fructose-6-phosphate aminotransferase 1 (GFAT1), is a direct
target of the UPR protein Xbp1s. Xbp1s overexpression in vivo
significantly enhanced HBP flux and O-GlcNAc modification.
Moreover, we report that Xbp1s is sufficient and necessary to
protect heart from I/R injury, and GFAT1 is required for this
cardioprotective response. Collectively, our results provide the
first evidence for mechanistic coupling of the UPR and HBP,
as well as uncovering a previously unrecognized role of Xbp1s
in conferring robust cardioprotection from I/R injury.
RESULTS
O-GlcNAc Protein Modification and HBP Are Induced by
Cardiac I/R
The catalytic activity of OGT is highly sensitive to changes in
UDP-GlcNAc levels, and as such, increased flux through the
HBP can drive increases in O-GlcNAc protein modification
(Boehmelt et al., 2000; Kreppel and Hart, 1999). Numerous
studies have shown that acute induction of the HBP and
O-GlcNAc protein modification protects cells from a variety
of stresses, including heart disease (Darley-Usmar et al., 2012;
Zachara, 2012). I/R stress results in an increase in O-GlcNAc
protein modification in the ischemic region of the myocardium
(Ngoh et al., 2011). Using a murine model of cardiac I/R injury,Figure 1. Induction of HBP, O-GlcNAc Protein Modification, and the U
(A) Protein O-GlcNAcmodification was increased in the infarct zone of I/R-stresse
markers were elevated in the same region. GAPDH was used as loading control
(B) Protein expression and localization of GFAT1 were visualized by fluorescence
indicate cardiomyocytes in the ischemic region. Scale bars, 50 mm.
(C) Transcription of the HBP genes,GFAT1,GNPNAT1, andPGM3, as well asGalE
Sham samples of 4 hr and 24 hr were pooled and used as control. n = 3–9.
(D) Transcription of UPR genes was induced in the infarct region of heart during
(E) Xbp1s was increased in the infarct region of I/R-stressed heart. Lamin was use
signal across all samples.
(F) Xbp1s mRNA levels were reduced in human heart following LVAD mechanica
See also Figure S1 and Table S2.we triggered this I/R-induced increase in O-GlcNAc protein
modification and assessed whether induction of HBP enzymes
is a driving force underlying increased HBP flux.
Wild-type (WT) male mice were subjected to cardiac ischemia
for 45 min followed by reperfusion overnight (24 hr). Hearts were
separated into three regions: ischemic, border, and remote,
according to previous triphenyltetrazolium chloride (TTC) stain-
ing patterns. Examination of the ischemic region confirmed
that O-GlcNAc protein modification was increased 2-fold as
compared with the border zone, remote region, and sham-oper-
ated hearts (Figure 1A). This increase in O-GlcNAc modification
was apparent as early as 4 hr after reperfusion (Figure S1A
available online). The specificity of the O-GlcNAc antibody was
verified by antigen competition (Figure S1B). These data are
consistent with previous reports demonstrating augmentation
of O-GlcNAc modification by ischemic stress in vitro and in vivo
(Champattanachai et al., 2007, 2008; Ngoh et al., 2011) and
establish persistence of this modification in I/R-stressed mouse
heart for at least 24 hr.
We next measured the abundance of HBP enzymes in these
hearts. Levels of GFAT1, the rate-limiting enzyme of the HBP
(Figure S1C), were significantly increased in the ischemic region,
as shown by immunoblotting and immunofluorescence staining
(Figures 1A, 1B, and S1D). Furthermore, the increased steady-
state levels of GFAT1 protein mirrored the increased O-GlcNAc
modification within the time points examined (Figures 1A
and S1A). Examination of transcript levels confirmed the in-
crease in GFAT1 specifically in the ischemic region (Figure 1C).
By examining all members of the HBP pathway, we found
that two additional key enzymes, were also upregulated, viz.
glucosamine-phosphate N-acetyltransferase (GNPNAT1) and
phosphoglucomutase 3 (PGM3) (Figures 1A, 1C, and S1A).
In addition, transcript and protein levels of UDP-glucose 4-epi-
mease (GalE), the enzyme that drives conversion between
UDP-GalNAc and UDP-GlcNAc and thereby contributes to the
pool of UDP-GlcNAc, were also significantly increased (Figures
1A, 1C, and S1A). Together, these data suggest that transcrip-
tion of genes coding for key enzymes of the HBP is significantly
upregulated in the ischemic region of heart in a time course
similar to O-GlcNAc protein modification. Further, they suggest
that the O-GlcNAc protein modification is driven by increased
HBP flux during I/R stress in the heart.
GFAT1 Is a Direct Target of Xbp1s
UDP-GlcNAc, the end product of the HBP, serves not only as the
substrate for O-GlcNAc modification, but also as a critical donorPR in Heart by I/R
d heart. Protein levels of the hexosamine biosynthetic pathway (HBP) and UPR
. n = 3 for each group.
immunostaining in heart tissue from sham-operated and I/R animals. Arrows
, was induced in the infarct region of heart during I/R as assessed by qRT-PCR.
I/R as assessed by qRT-PCR. n = 3–9.
d as loading control for nuclear extracts. The asterisk (*) denotes a nonspecific
l support. n = 8. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01.
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Figure 2. GFAT1 Is a Direct Target of Xbp1s
(A) A conserved DNA motif, similar to the UPRE, was identified in the GFAT1 promoter from different species.
(B) GFAT1 promoter was stimulated by Xbp1s overexpression. The GFAT1 promoter activity was measured by a luciferase assay upon Xbp1s cotransfection in
HEK293T cells. n = 3 for each group.
(C) Xbp1s was associated with GFAT1 promoter. A ChIP assay was conducted in C2C12 cells after Xbp1s overexpression. PCR amplification was performed
using primers spanning the UPRE or from a distal region in the GFAT1 promoter. The triangles indicate increasing amounts of immunoprecipitated DNA for PCR
reaction.
(D)GFAT1 transcription was stimulated by Xbp1s in vitro. qPCRwas conducted to quantify relative mRNA levels ofGFAT1 after Xbp1s overexpression in NRVM.
n = 6.
(E) GFAT1 protein levels were elevated by Xbp1s induction. n = 3–4. Data are represented as mean ± SEM. *p < 0.05.
See also Figure S2.for protein glycosylation, which is necessary for proper protein
folding. These facts, combined with the realization that previous
studies reported UPR activation during cardiac ischemia (Qi
et al., 2007; Thuerauf et al., 2006), led us to investigate a possible
link between the HBP and the UPR. Immunofluorescence stain-
ing for theERstresschaperoneBiP revealed significant increases
in the ischemic zone (Figure S1D). Examination of protein levels
by immunoblotting revealed an increase in BiP and additionally
showed that other UPR target proteins, GRP94 and CHOP,
were also significantly upregulated (Figures 1A and S1A).
Increases in protein levels were accompanied by significant in-
creases in their transcripts (Figure 1D). Interestingly, the pattern
of transcriptional response of the UPR target genes matched
that observed for the HBP genes in both location and timing.
Additionally, the transcription factor Xbp1s, a driver of UPR
gene expression, was significantly induced as early as 5 min
postreperfusion and increased 6-fold by 4 hr (Figure 1D). An
increase in Xbp1s protein levels in the ischemic zone was also
observed by immunoblotting (Figure 1E). Together, these results
confirm that theUPR is activated in the ischemic zone ofmyocar-1182 Cell 156, 1179–1192, March 13, 2014 ª2014 Elsevier Inc.dium during I/R in vivo and suggest a link between the transcrip-
tional control of the HBP pathway and UPR target genes.
To examine whether the increased expression of Xbp1s was
relevant to human disease, we examined levels of Xbp1s in
myocardial samples from patients with end-stage heart failure.
Samples were obtained from patients prior to left ventricular
assist device implantation, and a second sample from the
same patient was obtained after the device was removed for
transplantation. Quantitative RT-PCR (qRT-PCR) analysis re-
vealed significant expression of Xbp1s in the stressed hearts,
which was uniformly decreased in all samples after mechanical
unloading with assist device support (Figure 1F).
Having demonstrated that both the UPR and HBP are
increased during I/R, we next tested for a link between these
two processes. We first focused on GFAT1, the rate-limiting
enzyme of the HBP. Sequence analysis of the GFAT1 promoter
uncovered a region at 270 bp, which is highly conserved and
is similar to the consensus sequence of the unfolded protein
response element (UPRE), an established Xbp1s binding site
(Figure 2A) (Yamamoto et al., 2004). To test whether the
GFAT1 promoter could be activated by Xbp1s, we subcloned the
promoter of mouse GFAT1 into a luciferase reporter vector. Co-
expression of Xbp1s dramatically increased luciferase activity in
HEK293T cells in a dose-dependent fashion, suggesting that
Xbp1s directly stimulates the transcription of GFAT1 (Figure 2B).
To corroborate this finding, we expressed Xbp1s in C2C12 cells
and performed chromatin immunoprecipitation (ChIP) analysis
(Figure S2A). Semiquantitative PCR showed enrichment of the
GFAT promoter region in the Xbp1s precipitate (Figure 2C).
These results establish occupancy by Xbp1s on the endogenous
GFAT1 promoter.
To verify this relationship in cardiomyocytes, we infected
neonatal rat ventricular myocytes (NRVM) in culture with lenti-
virus expressing either LacZ or Xbp1s. Expression of Xbp1s trig-
gered robust upregulation of GFAT1 at both mRNA and protein
levels (Figures 2D and 2E). Collectively, these results reveal
that GFAT1 is a direct transcriptional target of Xbp1s.
Xbp1s Is an Upstream Activator of the HBP
Transcript and protein levels of the HBP-related enzymes,
GNPNAT1, PGM3, and GalE, were also increased in the infarct
region of myocardium following I/R (Figures 1A and 1C). More-
over, expression of Xbp1s in NRVM led to a significant upregula-
tion of these transcripts (Figure S2B). The induction of a number
of HBP genes by I/R and Xbp1s overexpression suggests
a common mechanism. Examination of the promoters of the
GNPNAT1, PGM3, and GalE genes uncovered a conserved
DNA motif consistent with a UPRE (Figure S2C) and consistent
with our previous findings (Deng et al., 2013). Moreover, lenti-
virus-mediated overexpression of Xbp1s in NRVM triggered
increases in O-GlcNAc protein modification (Figure S2D).
Additional analysis of other enzymes from the HBP pathway,
including GLUL1, GPI1, and UAP1, did not reveal consistent
induction in the ischemic region of I/R hearts or in hearts from
Xbp1s transgenic mice (vide infra); further, a conserved UPRE
was not found in the promoter or intron regions (Figures S2E
and S2F). Likewise, O-GlcNAcase (OGA), the enzyme that cata-
lyzes removal of O-GlcNAc from proteins, was not altered by
Xbp1s overexpression (Figure S2F). Collectively, these results
suggest that Xbp1s is a key regulator of HBP flux by activating
transcription ofmultiple enzyme-encoding genes in the pathway.
Increases in O-GlcNAc Modifications Correlate with
UPR Activation in a Wide Range of Stress Conditions
O-GlcNAc modification is known to play an important role in
the cellular response to stress, above and beyond cardiac I/R.
Our data suggest that activation of the UPR may be a universal
link between O-GlcNAc modification and the cellular stress
response. To test this, we examined a number of stress condi-
tions in which O-GlcNAc protein modification has been reported
to be increased. COS-7 cells were serum-starved overnight and
then treated with NaCl (100 mM), CoCl2 (50 mM), or sodium arse-
nite (75 mM) for 8 hr. Consistent with previous findings (Zachara
et al., 2004), we observed an increase in O-GlcNAc modification
(Figure S3A). Also, we found expression levels of BiP, the
classical marker of the UPR, were significantly elevated. Thus,
activation of O-GlcNAc protein modification correlates with the
induction of the UPR. To extend these observations, we firstdetermined that Xbp1s was indeed induced by these stress
treatments. Next, we tested the requirement for Xbp1s in this
process by small interfering RNA (siRNA)-induced silencing.
Knockdown of Xbp1s led to a significant reduction in stress-
mediated augmentation of O-GlcNAc modification (Figure S3B).
These data provide strong support for a universal link
between UPR activation and increased cellular O-GlcNAc pro-
tein modification.
Recent studies demonstrate that glucose deprivation in
NRVM leads to robust upregulation of O-GlcNAc modification
(Zou et al., 2012). We subjected NRVM to glucose starvation
for 18 hr. Protein O-GlcNAc modification was increased, which
correlated with BiP induction (Figure S3C). Further, knockdown
of Xbp1s significantly diminished starvation-induced increases
in O-GlcNAc modification (Figure S3D). These data lend addi-
tional support to the notion that the UPR is a generalizeable, up-
stream trigger of the HBP and O-GlcNAc modifications.
We also examined the effects of known ER stress inducers
on O-GlcNAc protein modification. Consistent with a model in
which Xbp1s is an upstream activator of the HBP and O-GlcNAc
modification, thapsigargin (Tg), tunicamycin (TM), or dithiothrei-
tol (DTT) each significantly augmented O-GlcNAc levels (Fig-
ure S3E). Knockdown of Xbp1s prior to administration of each
ER stress inducer significantly attenuated GFAT1 induction
and O-GlcNAc modification (Figure S3F). Thus, induction of ER
stress is itself a bona fide trigger, through Xbp1s, of cellular
O-GlcNAc protein modification.
Althoughour in vitrodata strongly support a generalmodel link-
ing the UPR and HBP, we set out to determine whether Xbp1s
induction is correlated with HBP upregulation and increases in
O-GlcNAc modification in models beyond I/R in vivo. TM is a
potent inhibitor of protein N-Glycan synthesis and a well-estab-
lished inducer of ER stress. We injected TM into adult male
mice and harvested hearts 24 hr later, noting robust upregulation
of genes involved in the UPR (Figure S3G). Importantly, we found
enzymes within the HBP pathway and O-GlcNAc protein modifi-
cation were also significantly increased. These results indicate
that induction of Xbp1s, elicited by conditions other than I/R, is
correlated with augmentation of the HBP and O-GlcNAc modifi-
cation in heart. Collectively, these data, then, point to a direct
link between activation of the UPR elicited by a variety of cellular
stresses and increases in O-GlcNAc protein modification.
Cardiomyocyte-Specific Xbp1s Expression Drives HBP
Flux and O-GlcNAc Protein Modification In Vivo
To test the link between the UPR and HBP flux in vivo, we engi-
neered mice to induce Xbp1s expression specifically in cardio-
myocytes. These animals harbored the Xbp1s coding sequence,
with expression driven by seven tetracycline responsive ele-
ments. By breeding with cardiomyocyte-specific aMHC-tTA
transgenic mice, Xbp1s is expressed only in cardiomyocytes
and suppressed in the presence of doxycycline (Dox) (Figure 3A).
These animals (including breeding pairs) were maintained
on Dox-containing water to prevent transgene expression, and
induction of Xbp1s was accomplished by removing Dox from
the water supply.
To test the fidelity of this system, we evaluated all possible
combinations of transgene and Dox. Only the double transgenicCell 156, 1179–1192, March 13, 2014 ª2014 Elsevier Inc. 1183
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Figure 3. Xbp1s Drives GFAT1 Expression
In Vivo
(A) Inducible overexpression of Xbp1s in car-
diomyocytes in vivo. Xbp1s expression was sup-
pressed by doxycycline (Dox).
(B) GFAT1 transcription was significantly induced
by Xbp1s overexpression. Control (aMHC-tTA
only) and TG (aMHC-tTA, TRE-Xbp1s double
transgenic) mice were placed on regular water
(1–3 weeks) to stimulate Xbp1s expression. Car-
diac GFAT1 mRNA levels were quantified by qRT-
PCR. n = 3.
(C) GFAT1 protein expression was compared be-
tween control and TG mouse hearts after 2 week
induction of Xbp1s. GAPDH was used as loading
control. n = 3. Data are represented as mean ±
SEM. *p < 0.05.
(D) GFAT1 protein levels and expression patterns
were assessed by immunostaining. Scale bars,
50 mm.
See also Figure S4.mice in the absence of Dox manifested induction of Xbp1s (Fig-
ure S4A), confirming the efficiency, tightness, and specificity of
the system. Xbp1s protein abundance in these animals was
3-fold higher than that induced by I/R (Figures 1E and S4B).
Consistent with functional expression of the transgene, the
downstream target of Xbp1s, BiP, was significantly induced (Fig-
ure S4C). We induced Xbp1s for 1–3 weeks and found that
GFAT1 manifested 10-fold induction in mRNA levels and 5-fold
increases in protein levels (Figures 3B and 3C). Immunofluores-
cence staining for GFAT1 protein confirmed the gene expression
changes (Figures 3D and S4D). In contrast, GFAT2, the other
member of the GFAT family, was not upregulated by Xbp1s
but rather displayed a trend toward decreased abundance,
possibly due to compensation for GFAT1 induction (Figure S4E).
Xbp1s Induction Leads to Increases in Nucleotide
Sugars and O-GlcNAc Modification
We next set out to determine whether Xbp1s-dependent activa-
tion of the HBP leads to increases in the nucleotide sugar end
products of the pathway. We isolated free UDP-sugars from
hearts and analyzed them by fluorophore-assisted carbohydrate
electrophoresis (FACE) (Gao and Lehrman, 2006). Free nucleo-
tide sugars of UDP-Glucose (UDP-Glc) and UDP-GlcNAc were
significantly increased in Xbp1s transgenics relative to control
mice (Figures 4A and S4F).
We next evaluated the O-linked monosaccharide composition
of covalently modified proteins. Total proteins were isolated from
control and transgenic mouse hearts and processed for b-elim-
ination to cleave modified sugars. After separation by FACE,
we detected significant increases in O-Glc and O-GlcNAc
monosaccharide levels (Figures 4B and S4G).
The obligate substrate UDP-GlcNAc is transferred to accept-
ing residues by OGT, and OGT enzymatic activity and O-GlcNAc
protein modification are largely dependent on intracellular free
UDP-GlcNAc levels. Consistent with the elevated levels of free
UDP-GlcNAc in transgenic hearts, O-GlcNAc protein modifica-
tion was significantly increased (Figure 4C). These data demon-1184 Cell 156, 1179–1192, March 13, 2014 ª2014 Elsevier Inc.strate that increased Xbp1s expression is sufficient to drive HBP
flux and O-GlcNAc protein modification in heart.
UDP-GlcNAc is an important precursor of N-Glycan and
O-Glycan sugars. FACE analysis showed a moderate but signif-
icant increase in total neutral N-Glycan in transgenic mice
(Figure S4H). These findings are consistent with upregulation
of the HBP and GalE, as the latter is the epimerase that orches-
trates the balance between UDP-Glc and UDP-Gal and between
UDP-GlcNAc and UDP-GalNAc. No difference in negatively
charged N-Glycan or O-Glycan was detected (data not shown).
Together, these results reveal strong induction of O-GlcNAc pro-
teinmodification and significant increases in neutral N-Glycan by
Xbp1s overexpression in heart, thereby supporting a model in
which increases in the HBP pathway during cell stress are driven
by Xbp1s. Further, the orchestrated upregulation of multiple
enzymes involved in the synthesis and interconversion of UDP-
sugars provides a satisfying explanation for the increases in
N-Glycan species, which may contribute to enhanced protein
folding and relief of ER stress.
Xbp1 Is Required for Induction of HBP and O-GlcNAc
Protein Modification
Our data point to a model in which activation of the UPR by I/R
triggers Xbp1s-dependent activation of the HBP and increased
O-GlcNAc proteinmodification. To investigate this further in vivo,
we engineered a mouse line harboring a cardiomyocyte-specific
silencing construct of Xbp1 by crossing mice in which the Xbp1
locus is floxed with aMHC-Cre transgenic mice (cardiomyocyte-
specific knockout [cKO]). DNA from isolated cardiomyocytes
manifested 90% recombination efficiency in cKO cardio-
myocytes, as measured by semiquantitative PCR analysis. No
detectable excision was identified in F/F myocytes or in noncar-
diomyocytes (Figures S5A and S5B).
Xbp1 silencing caused no significant changes in basal levels of
GFAT1, GNPNAT1, PGM3, GalE, or a number of UPR markers
(Figure S5C). This is consistent with our findings where Xbp1
was silenced by siRNA in vitro (Figure S5D). Moreover, when
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Figure 4. Xbp1s Induction Leads to In-
creases in Nucleotide Sugars andO-GlcNAc
Modification
(A) Induction of Xbp1s in cardiomyocytes led to
significant increases in free nucleotide sugars in
heart. Control and TGmice were placed on regular
water (2 weeks) to stimulate Xbp1s expression.
Free nucleotide sugars were analyzed by FACE.
Samples corresponding to equal amount of total
cellular proteins were loaded for each mouse
strain. n = 6.
(B) Induction of Xbp1s in cardiomyocytes led
to augmentation of O-Glc and O-GlcNAc pro-
tein modifications. Total cellular O-linked mono-
saccharides were separated by FACE gel. n = 6 for
each group.
(C) Cardiac induction of Xbp1s led to significant
increases in O-GlcNAc protein modification, as
evaluated by immunoblotting for O-GlcNAc.
GAPDH was used as loading control. n = 6 for
control and n = 8 for TG mice. Data are repre-
sented as mean ± SEM. *p < 0.05, **p < 0.01.
See also Figure S4.we subjected the heart samples to FACE, no significant differ-
ences were found in either free nucleotide sugars or O-linked
modifications (Figure S5E). Consistently, O-GlcNAc protein
modification did not differ (Figure S5F).
These cKO animals and littermate controls were then sub-
jected to I/R surgery. I/R-induced GFAT1 protein expression
was significantly attenuated in the cKO mice (Figure 5A). I/R in-
duction of GNPNAT1, PGM3, and GalE was also significantly
reduced by Xbp1 silencing. Likewise, ER stress markers were
less abundant (Figure 5B). Consistent with less induction of
HBP genes in cKO hearts, protein O-GlcNAc levels after I/R
were significantly reduced (Figure 5C). These data demonstrate
a requirement for Xbp1s in the induction of HBP and O-GlcNAc
protein modification after I/R.
The requirement of Xbp1s in TM-induced upregulation of the
HBP and O-GlcNAc modification was also examined. TM trig-
gered potent upregulation of UPR markers, enzymes within the
HBP pathway, and protein O-GlcNAc modification in F/F hearts
(Figure S3H). As anticipated, this response was significantly
blunted by loss of Xbp1 in cKO hearts. These data, then, high-
light the importance of Xbp1s in ER stress-induced activation
of the HBP and resulting increases in O-GlcNAc protein
modification.
Xbp1s Induction Is Sufficient and Necessary to Protect
Heart from I/R Injury In Vivo
We have shown that the UPR is robustly induced in heart by
I/R, consistent with previous findings (Thuerauf et al., 2006).
Although a number of in vivo studies have focused on the
ATF6 pathway in response to ischemia (Doroudgar et al., 2009;
Martindale et al., 2006), a specific role for the IRE1/Xbp1s
pathway in heart during I/R has not been reported.
To investigate this question, we subjected cKO animals to car-
diac ischemia for 45 min followed by reperfusion overnight. TTC
staining was performed to measure infarct size and area at risk.
These experiments revealed a significant increase in myocyte
death in cKO mice compared with either F/F or aMHC-Crecontrols; greater than 30% increases in infarct size were seen
(Figures 6A and 6B). Surgical injury was similar in each line as
evidenced by similar areas at risk of infarction.
To test for functional relevance, we examined cardiac function
post-I/R. At baseline, myocardial function and morphology of
cKO hearts did not differ from control (Figures S5G and S5H).
Significant differences, however, did become apparent after
these mice were subjected to I/R. Echocardiographic analysis
revealed significant deteriorations in systolic performance,
quantified as percent fractional shortening, in cKO mice 7 days
post-I/R (Figure 6C). Left ventricular internal dimensions were
also greater in cKO hearts (Figure 6D). Gross analysis revealed
more profound cardiac hypertrophy in cKO mice, which was
corroborated by robust fetal gene reactivation (Figures 6E and
6F). These data, then, support a model in which induction of
Xbp1s during I/R is cardioprotective.
We next set out to address whether Xbp1s expression is suf-
ficient to drive cardioprotection from I/R injury, taking advantage
of our inducible transgenic mousemodel. Xbp1s expression was
induced by removal of Dox for 2 weeks. Echocardiographic anal-
ysis revealed no differences in baseline cardiac function (Fig-
ure S6A). After I/R, we observed dramatic protection against
ischemic injury by Xbp1s induction, with the infarct area of
the transgenic group reduced by nearly 50% (Figures 6G, 6H,
and S6B). No difference in area at risk was identified between
groups, confirming that the ischemic insult was similar. Func-
tionally, echocardiographic analysis showed that the transgenic
animals manifested significantly improved heart function 1 week
after I/R (Figure S6C). This result is anticipated by the observed
reduction in infarct size in the transgenic group. Collectively,
these data demonstrate that Xbp1s expression is necessary
and sufficient to protect the heart from I/R injury.
GFAT1 Is Required for Xbp1s-Dependent
Cardioprotection in I/R
We hypothesized that Xbp1s-driven augmentation of O-GlcNAc
proteinmodification contributes to the cardioprotective response.Cell 156, 1179–1192, March 13, 2014 ª2014 Elsevier Inc. 1185
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Figure 5. Xbp1s Is Required for Induction of
the UPR, the HBP, and O-GlcNAc Modifica-
tion in Heart after I/R
(A) Induction of the HBP genes, GFAT1,
GNPNAT1, and PGM3, as well as GalE was
analyzed in aMHC-Cre, F/F, and cKO hearts 24 hr
after I/R. n = 3–4 per group.
(B) Expression of the UPRmarkers BiP and GRP94
was analyzed 24 hr after I/R. n = 3–4.
(C) O-GlcNAc modification was reduced in cKO
hearts compared with controls. n = 3–4. Data are
represented as mean ± SEM. *p < 0.05.
See also Figures S3 and S5.To examine whether GFAT1 stimulation is required in this
process,wefirst turned toan invitromodel of I/RusingNRVM(Fig-
ure 7A). Simulated I/R (sI/R) was accomplished where NRVM
were exposed to ischemic conditions followedbyovernight reper-
fusion. We found sI/R effectively induced Xbp1s expression
(Figure 7B). To confirm that this model accurately mimics the
protective effects of Xbp1s observed in vivo, we reduced Xbp1s
levels by siRNA. Xbp1s knockdown led to significantly increased
cell deathasassessedbyLDH release (Figures7CandS7A).Addi-
tionally, overexpression of Xbp1s by lentiviral infection conferred
significant protection from sI/R injury (Figures 7D and S7B). These
data were corroborated by propidium iodide staining and ATP
measurements (Figures S7C–S7F). Together, these in vitro results
support our in vivo findings of the protective role of Xbp1s against
I/R injury and afforded us a tractable model with which to test the
role of the HBP pathway.1186 Cell 156, 1179–1192, March 13, 2014 ª2014 Elsevier Inc.As GFAT1 is the rate-limiting enzyme in
the HBP, we targeted GFAT1 as a means
of modulating the HBP. Consistent with
a model in which GFAT1 is a direct target
of Xbp1s, sI/R stimulated GFAT1 expres-
sion at both mRNA and protein levels
(Figure 7E). GFAT1 depletion by RNAi
significantly increased NRVM death (Fig-
ures 7F and S7G). Overexpression of
GFAT1 by lentivirus infection enhanced
cell survival against sI/R (Figures 7G
and S7H). In parallel experiments, we in-
fected NRVM with lentivirus-expressing
Xbp1s and reduced GFAT1 expression
by siRNA. Upon exposure to sI/R, we
found that GFAT1 knockdown signifi-
cantly diminished the protective effects
of Xbp1s (Figure 7H). Conversely, overex-
pression of GFAT1 rescued the cell death
observed under conditions of Xbp1s
knockdown (Figure 7I). These data sup-
port the role of the HBP in Xbp1s-depen-
dent cardioprotection.
UDP-GlcNAc is a final product of the
HBP. We therefore asked whether sup-
plementation of GlcNAc itself, thereby
bypassing the need for HBP induction,would rescue the loss of Xbp1s in I/R-induced cell death.We first
silenced Xbp1s by siRNA transfection and then subjected the
cells to sI/R. We supplemented GlcNAc during reperfusion.
Here, we found that GlcNAc significantly reduced Xbp1s knock-
down-induced cell death, highlighting the importance of GlcNAc
in the cardioprotection afforded by Xbp1s (Figure S7I).
OGT is the enzyme that catalyzes O-GlcNAc conjugation.
To further define the role of O-GlcNAc modification from other
possible protective effects of Xbp1s induction, we targeted
OGT in NRVM by siRNA. We found that silencing of OGT signifi-
cantly inhibited Xbp1s-mediated protection against sI/R damage
(Figure S7J). Collectively, these results indicate that O-GlcNAc
protein modification contributes significantly to the cardiopro-
tective actions of Xbp1s in I/R-stressed cardiomyocytes.
To further evaluate the dependence on GFAT1 of Xbp1s-
mediated cardioprotection, we next turned to the Langendorff
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Figure 6. Xbp1s Induction Protects Heart from I/R Injury In Vivo
(A) Xbp1 silencing led to increased injury from I/R. Male mice were subjected to I/R. Cardiac injury was assayed by TTC staining. Blue, unaffected, viable tissue;
red, area at risk; white, infarct area. Scale bars, 1 mm.
(B) Infarct area (relative to area at risk) and area at risk (relative to left ventricle) were quantified. Number of animals used is indicated.
(C) Ventricular function in cKO mice manifested significant deterioration as measured by % fractional shortening 7 days and 21 days post-I/R. n = 5 for F/F and
n = 7 for cKO.
(D) Left ventricular internal diameters (LVID) in diastole (left) and systole (right) were compared. n = 5–7.
(E) cKO mice developed more severe hypertrophy following I/R. n = 3–5. Scale bars, 2 mm.
(F) cKO mice manifested more robust fetal gene reactivation after I/R. n = 3–5.
(G) Xbp1s overexpression protected hearts from I/R injury. Control and TG mice were placed on normal water for 2 weeks to induce transgene expression. I/R
surgery was performed and cardiac injury was assessed by TTC staining. Scale bars, 1 mm.
(H) Infarct area (relative to area at risk) and area at risk (relative to left ventricle) were quantified. Data are represented asmean ±SEM. *p < 0.05, **p < 0.01. NS, not
significant.
See also Figure S5 and S6.
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Figure 7. GFAT1 Is Required for Xbp1s-Dependent Cardioprotection during I/R
(A) Experimental procedures for NRVM in vitro.
(B) Simulated I/R (sI/R)-induced Xbp1s expression as assessed by qRT-PCR. n = 3.
(C) Knockdown of Xbp1 led to enhanced cell death in response to sI/R. Xbp1s expression was reduced by siRNA. Cell death wasmeasured by LDH release. n = 3
for each group.
(D) Xbp1s overexpression protected cardiomyocytes from sI/R injury. NRVM were infected with lentivirus expressing either LacZ or Xbp1s. Cell death from sI/R
was quantified by LDH measurements. n = 6.
(E) GFAT1 mRNA and protein levels were significantly induced in NRVM after sI/R. n = 3.
(F) Knockdown of GFAT1 exacerbated sI/R injury. GFAT1 expression was reduced by siRNA. NRVMwere then subjected to sI/R, and cell death was assessed by
LDH release. n = 3.
(G) GFAT1 overexpression protected cardiomyocytes from sI/R injury. NRVMwere infected with lentivirus expressing either LacZ or GFAT1. Cell death from sI/R
was quantified by LDH measurements. n = 6 for each group.
(legend continued on next page)
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model in which the heart is isolated and undergoes controlled
I/R. Cardiac function is assessed by measuring contractile
strength by left ventricular developed pressure (LVDP). Cardio-
myocyte-specific Xbp1s overexpression conferred significant
protection during I/R as measured by LVDP recovery (Fig-
ure 7J). Azaserine, an enzymatic inhibitor of GFAT1, was
used at a concentration that does not affect basal cardiac func-
tion (Liu et al., 2007a). Azaserine treatment reduced the pro-
tective effect of Xbp1s in the transgenic hearts. Importantly,
azaserine did not completely abolish the protective effect of
Xbp1s expression in this assay, just as GFAT1 knockdown
did not abolish the cardioprotection observed in the sI/R exper-
iments (Figure 7H). Likewise, 6-diazo-5-oxo-l-norleucine (DON),
another inhibitor of GFAT1, showed similar suppression of
Xbp1s-mediated rescue of cardiac function (Figure S7K). These
data, then, suggest that additional pathways of protection are
triggered by the UPR during I/R (Glembotski, 2007; Groenen-
dyk et al., 2010; Minamino et al., 2010). Collectively, these re-
sults point to a critical role of GFAT1 in the beneficial effects
of Xbp1s, highlighting Xbp1s and activation of its transcriptional
targets in the HBP and consequent O-GlcNAc protein modifica-
tion as pivotal factors in the cellular response to I/R stress
(Figure S7L).
DISCUSSION
O-GlcNAc protein modification is a prevalent posttranslational
modification of numerous proteins and can modulate protein
stability and function. The enzyme responsible for this conjuga-
tion, OGT, is largely dependent on cellular free UDP-GlcNAc
levels for enzymatic activity. Thus, synthesis of UDP-GlcNAc
through the HBP is pivotal in regulating O-GlcNAc modification.
Here, we report that Xbp1s, a highly active transcription factor
of the UPR, directly promotes transcription of the gene coding
for GFAT1, the rate-limiting enzyme of the HBP. We also pro-
vide evidence that Xbp1s activates transcription of two addi-
tional enzyme-encoding genes within the HBP, viz. GNPNAT1,
PGM3, and the related gene, GalE. Xbp1s strongly induces
HBP flux, as revealed by increases in free UDP-GlcNAc and
O-GlcNAc protein modifications. Further, we show that Xbp1s,
the most highly conserved arm of the UPR, is induced during
I/R in heart. Using a combination of gain- and loss-of-function
strategies, we demonstrate that this response confers robust
cardioprotection, serving to preserve myocyte viability and
contractile function. Finally, we show that Xbp1s-dependent car-
dioprotection is largely dependent on GFAT1. Together, these
studies uncover a mechanistic axis directly linking the UPR,
HBP, O-GlcNAc protein modification, and associated cell sur-
vival under stress conditions.(H) GFAT1 knockdown diminished Xbp1s cardioprotection in sI/R. NRVM were fi
sI/R, LDH assays were conducted. n = 3.
(I) Overexpression of GFAT1 significantly rescued cell death by Xbp1 silencing. N
siRNA. After sI/R, cell death was quantified by LDH assay. n = 6 for each group.
(J) Inhibition of GFAT1 diminished cardioprotection by Xbp1s. Control and TG
reperfusion 40min). Cardiac function was assessed as left ventricular developed p
and n = 4 for TG + Az. Data are represented as mean ± SEM. *, TG versus contr
See also Figure S7.Approximately 5% of glucose entering cells may be metabo-
lized through the HBP; under certain conditions, the HBP contri-
bution can be significantly higher (Darley-Usmar et al., 2012;
Slawson and Hart, 2011). After uptake, glucose is fixed by
phosphorylation and metabolized by various pathways. In the
HBP, GFAT transfers the amine moiety from glutamine to fruc-
tose-6-phosphate. Subsequently, glucosamine-6-phosphate is
modified by GNPNAT to generate N-acetylglucosamine-6-phos-
phate, which is rapidly converted to the ultimate product of the
HBP, UDP-GlcNAc (Wells and Hart, 2003).
UDP-GlcNAc is the obligate substrate for O-GlcNAc protein
modification, which has attracted considerable attention due to
its immediate association with developmental and disease con-
ditions (Slawson and Hart, 2011; Wells and Hart, 2003). Indeed,
O-GlcNAcmodifications canmodulate protein stability and func-
tion and are implicated in various diseases, including diabetes,
neurodegeneration, and cardiovascular disease (Darley-Usmar
et al., 2012; Lazarus et al., 2009). Multiple lines of evidence sug-
gest that O-GlcNAc modification is increased in various cardiac
diseases and that this increase may be protective (Champatta-
nachai et al., 2008; Jones et al., 2008; Laczy et al., 2010; Liu
et al., 2007b; Ngoh et al., 2009a; Watson et al., 2010). However,
prior to this report, mechanisms triggering the upstream HBP
synthetic cascade have remained elusive.
OGT manifests significantly higher affinity for UDP-GlcNAc
compared to several other enzymes of UDP-GlcNAc-consuming
reactions (Darley-Usmar et al., 2012). Moreover, deficiency of
GNPNAT1 leads to substantial reductions in UDP-GlcNAc levels,
which translate into decreased O-GlcNAc modification (Boeh-
melt et al., 2000). OGT activity and O-GlcNAc levels are largely
dependent on free UDP-GlcNAc levels (Kreppel and Hart,
1999). Data reported here provide direct evidence that Xbp1s
stimulates the HBP pathway, which leads to increases in UDP-
GlcNAc production and O-GlcNAc modification. Interestingly,
O-GlcNAc modification has been shown to reduce ER stress-
induced cell death in cardiomyocytes (Ngoh et al., 2009b). Like-
wise, GlcNAc treatment can significantly attenuate cell death
elicited by glucose deprivation and UPR activation, suggesting
a possible feedback role for HBP flux in antagonizing the detri-
mental effects of ER stress (Palorini et al., 2013).
The UPR is a ubiquitous response to a variety of cellular in-
sults, many of which provoke protein folding stress (Schro¨der
and Kaufman, 2005). Even under physiological conditions, the
UPR toggles on and off to cope with the normal protein folding
demands of cell growth and proliferation. The UPR is an elegant
and complex response to transduce signaling from the affected
organelles (e.g., ER for ER stress) to the nucleus for restoration of
homeostasis. At least three UPR branches have been described
in the ER. The IRE1/Xbp1s branch in mammals functions torst infected with LacZ or Xbp1s lentivirus. GFAT1 was reduced by siRNA. After
RVM were first infected with LacZ or GFAT1 lentivirus. Xbp1 was reduced by
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01.
mouse hearts were processed for Langendorff analysis (ischemia 20 min;
ressure (LVDP). n = 7 for control, n = 4 for TG, n = 4 for control + Azaserine (Az),
ol, p < 0.05. #, TG versus TG + Az, p < 0.05.
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resolve protein-folding stress and restore ER homeostasis in
multiple cell types under various conditions (Casas-Tinto et al.,
2011; Hess et al., 2011; Iwakoshi et al., 2003; Kaser et al.,
2008; Romero-Ramirez et al., 2004; Thuerauf et al., 2006).
In heart, restoration of coronary blood flow is critical in limiting
damage due to acute myocardial infarction and improving clin-
ical outcomes. A large body of literature, however, reveals that
reperfusion paradoxically triggers lethal damage to cardiomyo-
cytes (Hausenloy and Yellon, 2013; Murphy and Steenbergen,
2008; Yellon and Hausenloy, 2007). Despite this fundamental
fact, no therapies targeting reperfusion injury are available for
clinical use. Calcium mishandling in both the cytosol and mito-
chondria and mitochondrial ROS over-production are among
the most critical contributors to the pathogenesis of I/R injury.
Importantly, both of these events are well-established inducers
of protein misfolding and the UPR. Indeed, Glembotski and col-
leagues (Doroudgar et al., 2009; Martindale et al., 2006; Thuerauf
et al., 2006) have reported upregulation of ER chaperones upon
I/R in both in vitro and ex vivo models, highlighting the possible
involvement of the UPR in I/R pathogenesis. Here, we employed
an in vivo approach, finding that UPR chaperones are stimulated
in the ischemic zone of I/R-stressed tissue. Additionally, we pro-
vide evidence that the UPR is activated in human hearts under
stress.
Using both gain- and loss-of-function strategies, we show
that Xbp1s induction protects the heart from I/R injury in vivo.
Xbp1s is a powerful transcription factor, targeting an array of
ER chaperones and a group of molecules involved in ERAD.
Mechanistically, these proteins may serve as a link between
Xbp1s and cellular protection. Overexpression of the ER chap-
erone BiP in cardiomyocytes in vitro reduces cell death trig-
gered by proteasome inhibition (Fu et al., 2008). Similar findings
have been reported for the chaperone PDI (Severino et al.,
2007). Even brief pharmacological stimulation of ER stress
using tunicamycin can improve heart function during I/R in vivo
(Petrovski et al., 2011). All these reports indicate that ER chap-
erones may mediate, at least in part, the cardioprotective
actions of Xbp1s. Involvement of other pathways was largely
unknown.
Whereas protein chaperones and ERAD contribute impor-
tantly to protein homeostasis, protein folding also requires
proper posttranslational glycosylation. Nucleotide sugars are
intermediate substrates of glycosylation and their abundance
and relative concentrations are significant determinants of pro-
tein folding. Among them, UDP-GlcNAc is synthesized de novo
by the HBP.Moreover, proper ratios of UDP sugars are governed
by the epimerase GalE. We have shown here that GFAT1, the
rate-limiting enzyme of the HBP, and GalE are direct targets of
Xbp1s. Thus, HBP activation and control of the relative abun-
dance of nucleotide sugars may contribute significantly to the
beneficial effects of Xbp1s during I/R.
Our data strongly suggest that O-GlcNAc protein modification
contributes to Xbp1s-mediated cardioprotection against I/R. At
least one major question remains: how does O-GlcNAc modifi-
cation protect the cell? GlcNAc, a molecule containing a sugar
backbone, an amine group, and an acetyl group, is a unique
cellular element, potentially serving as a reservoir of basic nutri-
ents. Moreover, O-GlcNAc targets Ser/Thr residues formodifica-1190 Cell 156, 1179–1192, March 13, 2014 ª2014 Elsevier Inc.tion, which may either suppress or enhance phosphorylation
(Hart et al., 2011). The cardioprotection mediated by O-GlcNAc
modification during I/R may stem, at least in part, from its
modulation of phosphorylation of key elements in the cell death
pathway.
In conclusion, Xbp1s is a direct inducer of the HBP and, as a
consequence, O-GlcNAcmodification. Xbp1s is induced in heart
during I/R in vivo, and Xbp1s exerts robust cardioprotection
against I/R injury. Thus, our findings uncover a direct mecha-
nistic link between the UPR, the HBP, O-GlcNAc modification,
and cardioprotection.
EXPERIMENTAL PROCEDURES
Animals
WT male mice (8–12 weeks old) of C57/B6 background were used for
ischemia/reperfusion surgery. The TRE-Xbp1s transgenic mouse was gener-
ated in FVB and then backcrossed into C57/B6 background for at least 9
generations (Deng et al., 2013). We crossed the TRE-Xbp1s mouse with the
aMHC-tTA mouse model (Yu et al., 1996). Floxed Xbp1 mice (Kaser et al.,
2008) were bred with aMHC-Cre mice to achieve cardiomyocyte-specific
deletion of Xbp1.
Cardiomyocyte Isolation and Treatment
Neonatal rat ventricular cardiomyocytes (NRVM) were isolated from 1- to 2-
day-old Sprague-Dawley rat pups. For simulated I/R, cells were changed to
I/R buffer and placed in a hypoxia chamber (Billups-Rothenberg) and flushed
with 95% N2/5% CO2 for 30 min. The chamber was closed for an additional
3.5–4.5 hr, followed by reperfusion with culture medium. NRVM incubated
with control buffer were used as controls. LDH assays were conducted using
the CytoTox96 cytotoxicity kit (Promega). Cell survival was also measured by
the CellTiter-Glo viability assay kit (Promega) and propidium iodide staining
(1 mg/ml).
RNA Isolation and PCR Analysis
Total RNA was isolated from heart tissue or NRVM using the Total RNA
Fatty and Fibrous Tissue Kit (Bio-Rad). All primer sequences are provided
(Table S1).
Immunoblotting
Heart tissue lysate was prepared in T-PER (Thermo) containing protease
inhibitors and phospho-STOP (Roche). When preparing lysate for O-GlcNAc
analysis, PUGNAc (40 mM) was included to inhibit OGA activity. To isolate
nuclear extracts, the NE-PER kit was used (Thermo). Immunoblotting was
done with an Odyssey scanner (LI-COR).
Langendorff Experiments
Heart was quickly removed and the aorta was cannulated on a blunted 21
gauge needle. Ischemiawas initiated by arresting perfusion for 20min followed
by reperfusion for 40 min. Left ventricular pressure was recorded with a pres-
sure transducer using a ventricular balloon. Azaserine (80 mM) or 6-diazo-
5-oxo-l-norleucine (DON) (50 mM) was employed to inhibit GFAT enzymatic
activity.
Nucleotide Sugar and Protein Glycosylation Analysis in Heart
Snap-frozen heart tissue was pulverized directly in methanol, dried, and ex-
tracted with chloroform:methanol, water, and chloroform:methanol:water.
The water fraction was collected for free nucleotide sugar analysis. The
remaining pellet was used to analyze sugar modification on proteins.
Patient Samples
Human heart tissue samples were obtained from patients with advanced heart
failure. Paired ventricular tissue samples were obtained from each patient at
the time of left ventricular assist device implantation and then at the time of
heart transplantation. Patient information is shown in Table S2.
Statistical Analysis
All datawere expressed asmean ±SEM. The Student’s t test was performed to
compare two groups. One-way ANOVA was used to analyze multiple groups.
Two-way ANOVA and subsequent Tukey tests were performed to analyze
time course studies. A p value less than 0.05 was considered as significant.
For additional details, see the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.cell.2014.01.014.
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